Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2241005 | 0.86 | SMN1; SMN2 (0.56) | SMN1; SMN2PKMCYP1A2CYP2C9CYP2D6 | |
| SCHEMBL13301273 | 0.86 | POLB (0.58) | SMN1; SMN2PKMCYP1A2CYP2C9CYP2D6 | |
| SCHEMBL23464918 | 0.84 | — | — | |
| SCHEMBL1564357 | 0.84 | SMN1; SMN2 (0.55) | SMN1; SMN2PKMCYP1A2CYP2C9CYP2D6 | |
| SCHEMBL1564354 | 0.84 | SMN1; SMN2 (0.55) | SMN1; SMN2PKMCYP1A2CYP2C9CYP2D6 | |
| SCHEMBL12385957 | 0.84 | SMN1; SMN2 (0.55) | SMN1; SMN2PKMCYP1A2CYP2C9CYP2D6 | |
| SCHEMBL14355657 | 0.82 | LMNA (0.59) | SMN1; SMN2PKMCYP1A2CYP2C9CYP2D6 | |
| SCHEMBL16420957 | 0.82 | SMN1; SMN2 (0.53) | SMN1; SMN2PKMCYP1A2CYP2C9CYP2D6 | |
| SCHEMBL23331595 | 0.82 | SMN1; SMN2 (0.67) | SMN1; SMN2PKMCYP1A2CYP2C9CYP2D6 | |
| SCHEMBL3009879 | 0.82 | SMN1; SMN2 (0.67) | SMN1; SMN2PKMCYP1A2CYP2C9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546383-B2 | Chiral fused [1,2]imidazo[4,5-c] ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120232057-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY | 2012-09-13 | — | — | US | disclosed |
| EP-1831226-B1 | CHIRAL TETRACYCLIC COMPOUNDS INDUCING INTERFERON BIOSYNTHESIS | 3M INNOVATIVE PROPERTIES CO (US) | 2012-08-08 | — | — | EP | disclosed |
| US-8207162-B2 | Chiral fused [1,2]imidazo[4,5-c] ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-06-26 | — | — | US | disclosed |
| US-20110207725-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232057-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | IFNAR1, IFNG, IL4 | SMN1; SMN2 3046/4885PKM 4314/4885CYP1A2 768/4885 |
| US-20110207725-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | IFNAR1, IFNG, IL4 | SMN1; SMN2 2992/4885PKM 4315/4885CYP1A2 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.